スピラマイシンに関する魚病療法学的研究-1-ブリにおける吸収,分布,残留性および安全性

概要

論文の詳細を見る
1. ブリに対するSp の吸収, 体内分布, 排出, 残留性および安全性について調べた。 2. その結果, SpE, SpF, SpA はそれぞれ吸収が良く, 組織移行性が優れていることがわかった。 3. SpE のブリに対する急性毒性と亜急性毒性はほとんど認められず, 高い安全性が証明された。 4. SpE は胆汁排出型であり, 体内残留性が約10日間であることがわかった。Pharmacokinetic and toxicological examinations of spiramycin were studied in the cultured yellowtail. Spiramycin embonate (SpE) and free base (SpF) were orally administered and adipate (SpA) was intramuscularly injected. 1. The absorption, distribution and excretion data was obtained from the bioassay. All kinds of spiramycin were easily absorbed and quickly distributed in the blood and major organs. Peak levels were reached in 3 hours (SpA), 12 hours (SpF) and 24 hours (SpE) post dosing, followed by a gradual decrease. The levels in the liver, spleen, kidney and bile were higher than in the blood. The tissue levels were maintained for 7 - 10 days after the administration. 2. Acute and subacute toxicity studies of SpE were performed by oral administrations with free feeding. In the acute toxicity study the fish administered a single dose at the rate of 200, 400 and 800mg/kg survived without clinical and hidtological changes. In the subacute study the fish administered multiple doses at the rate of 40,80 and 400 mg/kg/day for 10 days survived without clinical and histological changes. 3. Minimal inhibitory concentration of SpE against Streptococcs sp. isolated from diseased yellowtail was in the range of 0.78 - 3.12μg/ml.
三重大学水産学部の論文

著者

窪田三朗
日本獣医畜産大

スピラマイシンに関する魚病療法学的研究-1-ブリにおける吸収,分布,残留性および安全性

スポンサーリンク

概要

著者

関連論文

スポンサーリンク